Entrada Therapeutics, Inc. Share Price

NASDAQ: TRDA

Small Cap

$5.28

-0.05

(-1.03%)

as on September 13, 2025 at 1:29 am IST

$₹

Entrada Therapeutics, Inc. Stock Performance

as on September 13, 2025 at 1:29 am IST

Day's Low
Day's High
$5.2
Day's Price Range
$5.49
$5.28
1.52%
Downside
3.98%
Upside
52 Week's Low
52 Week's High
$4.93
52-Week Price Range
$21.79
$5.28
6.63%
Downside
312.69%
Upside

Entrada Therapeutics, Inc. share price movements today

Previous Close: $5.33
Open: $5.29
Volume: 366.3K
Day's Low - High: $5.2 - $5.49
52 Week Low - High: $4.93 - $21.79

Entrada Therapeutics, Inc. Historical Returns

1 Month Return: -0.75 %
3 Month Return: -30.43 %
1 Year Return: -64.8 %
3 Year Return: -59.82 %
5 Year Return: 0 %

Entrada Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Entrada Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$202.7M

EPS (TTM)

-3.59

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

6.23

Industry PE ratio

-3.773885542168675

P/B Ratio

PEG Ratio

EBITDA

-92.3M

Revenue (TTM)

79.5M

Profit Margin

-92.30%

Return On Equity TTM

5149300.00%

Entrada Therapeutics, Inc. Stock Valuation

Track how Entrada Therapeutics, Inc. P/E has moved over time to understand its valuation trends.

Entrada Therapeutics, Inc. in the last 5 years

Overview
Trends

Lowest (4.80x)

June 30, 2024

Industry (-3.77x)

September 13, 2025

Today (6.23x)

September 13, 2025

Highest (22.44x)

March 31, 2024

LowHigh

Today’s Price to Earnings Ratio: 6.23x

Entrada Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Entrada Therapeutics, Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Entrada Therapeutics, Inc.	BUY	$202.7M	NA	6.23	-92.30%
Alnylam Pharmaceuticals, Inc.	BUY	$61.1B	280.5%	-505.15	-12.96%
Beone Medicines Ltd	NA	$37.7B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$101.2B	54.04%	28.08	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$59.4B	2.03%	14.11	31.37%

Stock Returns calculator for Entrada Therapeutics, Inc. Stock including INR - Dollar returns

The Entrada Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Entrada Therapeutics, Inc. investment value today

Current value as on today

₹40,339

Returns

₹59,661

(-59.66%)

Returns from Entrada Therapeutics, Inc. Stock

₹64,800 (-64.8%)

Dollar Returns*

₹5,139 (+5.14%)

Analyst Recommendation on Entrada Therapeutics, Inc. Stock

Based on 10 analysts

BUY

90.00%

Buy

10.00%

Hold

0.00%

Sell

Based on 10 analysts, 90% of analysts recommend a 'BUY' rating for Entrada Therapeutics, Inc.. Average target price of $18.5

Entrada Therapeutics, Inc. Share Price Target

Get share price movements and forecasts by analysts on Entrada Therapeutics, Inc..

What analysts predicted

71.46%UPSIDE

Target Price

$18.5

Current Price

$5.28

Analyzed by

10 Analysts

Target

$18.50

Entrada Therapeutics, Inc. target price $18.5, a slight upside of 71.46% compared to current price of $5.28. According to 10 analysts rating.

Entrada Therapeutics, Inc. Stock's Interest Amongst Investors

Search interest for Entrada Therapeutics, Inc. Stock has increased by 130% in the last 30 days, reflecting an upward trend in search activity.

Time period: August 15, 2025 to September 14, 2025

Change:130% versus previous 30 day period

Entrada Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	25	18	43	41	59	94	19	37	20	1
Gross Profit	24	17	42	41	58	93	18	36	20	0
Operating Income	1	-16	14	4	21	53	-21	-5	-21	-46
EBITDA	-5	-15	14	5	22	53	-21	-4	-20	-46
Interest Expense	4	-	-	4	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	1
Income Before Tax	-3	-12	18	9	25	57	-15	0	-17	-42
Income Tax Expense	3	13	-17	18	1	2	-1	-1	-	0
Net Income	-6	-25	35	-9	23	55	-14	1	-17	-43
Net Profit Margin	-26.42%	-142.70%	81.08%	-22.81%	39.74%	58.11%	-71.70%	3.02%	-84.39%	-2210.41%

Entrada Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	-	-	-	25	129	210
Gross Profit	0	0	-1	-1	29	210
Operating Income	-11	-26	-51	-97	-3	47
EBITDA	-11	-26	-50	-95	0	47
Interest Expense	-	-	0	2	-	-
Depreciation	0	0	1	1	2	3
Income Before Tax	-5	-26	-51	-94	12	66
Income Tax Expense	0	0	-1	-7	18	0
Net Income	-4	-26	-50	-87	-6	65
Net Profit Margin	0.00%	0.00%	0.00%	-346.23%	-5.18%	31.13%

Entrada Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-25	35	-9	23	55	-14	1	-17	-43
Operating Cash Flow	-35	-24	-4	-25	39	-24	-31	-38	-29
Investing Cash Flow	-113	-3	19	26	-24	-82	53	4	33
Financing Cash Flow	0	0	0	0	101	0	1	0	0
Change in Cash	-147	-27	15	0	116	-107	23	-33	4

Entrada Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-26	-51	-94	-6	65
Operating Cash Flow	-25	-50	-93	139	-41
Investing Cash Flow	-2	-4	-148	-138	-27
Financing Cash Flow	50	307	0	21	102
Change in Cash	22	252	-241	22	33

Global Institutional Holdings in Entrada Therapeutics, Inc.

Funds	Holdings
Baker Bros Advisors LP	12.79%
5AM Venture Management, LLC	11.59%
Mpm Asset Management, LLC	11.52%
T. Rowe Price Associates, Inc.	7.2%
HHG PLC	5.58%

See all

Insights on Entrada Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 125.6% return, outperforming this stock by 185.5%
NO EFFECT
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 75.7% return, outperforming this stock by 140.5%
NEGATIVE IMPACT
Price Dip
In the last 3 months, TRDA stock has moved down by -30.5%

About Entrada Therapeutics, Inc.

entrada therapeutics is building the leading intracellular biologics company to transform the treatment of devastating diseases. entrada was co-founded in 2016 by 5am ventures, a leading life sciences venture capital firm.

Organisation	Entrada Therapeutics, Inc.
Headquarters	One Design Center Place, Boston, MA, United States, 02210
Industry	Services
CEO	Mr. Dipal Doshi
E-voting on shares	Click here to vote

Key Management of Entrada Therapeutics, Inc.

Name	Title
Mr. Kevin Healy Ph.D.	Senior Vice President of Regulatory Affairs
Mr. Dipal Doshi	CEO & Director
Mr. Kory James Wentworth CPA	CFO & Treasurer
Dr. Jared Cohen J.D., Ph.D.	General Counsel
Ms. Karla MacDonald	Chief Corporate Affairs Officer
Mr. Nathan J. Dowden	President & COO
Dr. Natarajan Sethuraman Ph.D.	President of Research & Development
Ms. Kerry Robert M.S.	Senior Vice President of People
Sandeep Basnet	Head of Information Technology

FAQs

What is Entrada Therapeutics, Inc. share price today?

Entrada Therapeutics, Inc. share price today is $5.28 as on September 13, 2025 at 1:29 am IST at the close of the market. Entrada Therapeutics, Inc. share today touched a day high of $5.49 and a low of $5.2.

What is the 52 week high and 52 week low for Entrada Therapeutics, Inc. share?

Entrada Therapeutics, Inc. share touched a 52 week high of $21.79 on December 9, 2024 and a 52 week low of $4.93 on August 11, 2025. Entrada Therapeutics, Inc. stock price today i.e. September 13, 2025 at 1:29 am IST is closed at $5.28,which is 75.77% down from its 52 week high and 7.10% up from its 52 week low.

What is Entrada Therapeutics, Inc.'s market capitalisation today?

Entrada Therapeutics, Inc. market capitalisation is $0.00T as on September 13, 2025 at 1:29 am IST.

How to invest in Entrada Therapeutics, Inc. Stock (TRDA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Entrada Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Entrada Therapeutics, Inc. Shares that will get you 0.2841 shares as per Entrada Therapeutics, Inc. share price of $5.28 per share as on September 13, 2025 at 1:29 am IST.

What is the minimum amount required to buy Entrada Therapeutics, Inc. Stock (TRDA) from India?

Indian investors can start investing in Entrada Therapeutics, Inc. (TRDA) shares with as little as ₹88.27 or $1 (as of September 14, 2025 at 4:38 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹882.70 in Entrada Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on September 14, 2025 at 4:38 am IST). Based on Entrada Therapeutics, Inc. share’s latest price of $5.28 as on September 13, 2025 at 1:29 am IST, you will get 1.8939 shares of Entrada Therapeutics, Inc.. Learn more about fractional shares .